Tobira Therapeutics announced results from a 12-week interim analysis of the Phase 2a ORION study.
The study is examining the use of cenicriviroc to treat obese patients with prediabetes or diabetes and fatty liver disease. The interim data analysis of this study was based on 35 subjects. Over 50 percent of subjects were diagnosed with non-alcoholic fatty liver disease.
Here are three insights:
1. The study found that treatment with cenicriviroc was well tolerated and associated with improvements in insulin sensitivity.
2. Specifically, the study showed a reduction in fasting plasma glucose and HbA1c as well as a reduction of serum free fatty acid levels.
3. The study will continue as planned and the primary analysis will be based on 24-week data from all 45 subjects enrolled.